Navigation Links
Merz Pharmaceuticals Announces Approval of Post-stroke Upper Limb Spasticity Indication for Xeomin(R) in the EU
Date:11/18/2009

FRANKFURT, Nov. 18 /PRNewswire/ -- Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries. Xeomin® was already granted approval for post-stroke spasticity of the upper limb in early 2009 in Canada, Mexico and Argentina. This important extension of indication is based on the Kanovsky study, the largest randomized, placebo-controlled, double-blind trial with a botulinum toxin in upper limb post-stroke spasticity to date.

Data results published last month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin® in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity. The Phase III study assessed the impact of NT 201 on muscle tone, functional disability and caregiver burden in patients with post-stroke upper limb spasticity, utilizing a randomized, placebo-controlled, double-blind design.

NT 201 is high in biologic activity and has a low protein load. It has been approved for marketing in Europe since 2005 to treat various movement disorders, and recently approved in Canada for the management of blepharospasm, cervical dystonia of a predominantly rotational form and post-stroke spasticity of the upper limb.

In the Phase III trial, a higher proportion of patients receiving NT 201 were responders in terms of improvement in the wrist flexors four weeks after treatment. Responders were defined as patients with at least 1 point of improvement in the Ashworth Scale Score.

Dr. Alexander Gebauer, Chief Scientific Officer, Head of Global R&D, Merz Pharmaceuticals,
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
2. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
3. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
4. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
5. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
6. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
7. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
8. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
9. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
10. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
11. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... -- Donald Spector , a renowned celebrated entrepreneur ... a Wearable Biosensor, which will issue today, September 2, ... Mr. Spector holds some of the earliest patents in ... by New York College of Health Professions, which has ... intellectual properties.  New York College noted that the Wearable ...
(Date:9/2/2014)... , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... an overview of the company at the Morgan Stanley Global ... , Presentation date: Tuesday September 9, 2014 , ... live webcast and 30-day archive of this presentation will be ... Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
(Date:9/2/2014)... Today, Therapy Changes released ... Me?” The guide outlines common questions an individual may ... to common types of groups an individual can attend. ... the interventions of the therapist, but also from observing ... members,” says Rochelle Perper, Ph.D. and founder of Therapy ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud ... a contemporary marketing presence and visually solidifies the ... Friendship Senior Options,” said Stephen A. Yenchek, president ... the logo, we are making sure that our ... their families.” , Friendship Village is a retirement ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
(Date:9/2/2014)... return to the emergency department within a few days of ... symptoms and have lost trust in other parts of the ... published online today in Annals of Emergency Medicine ... ). , "When asked why they did not ... symptoms were too severe to wait until their scheduled appointment ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... ... Owens will be installed as the 86th president of the National Dental Association (NDA) at ... ... -- Nashville dentist Dr. Walter R. Owens will be installed as the 86th president of ...
... ... , ... (PRWEB) December 2, 2009 -- Perhaps the best medical advice to give consumers is ... keeping control of personal medical records is easier than ever. MyEMRChoice.com, a Fort Washington, ...
... ... medical device software engineering consulting firm Full Spectrum Software has received ... firms have actually achieved ISO 13485 certification. Many medical device makers ... well. However, it is somewhat rare for a medical device software ...
... Dec. 2 A randomized, controlled study comparing standard conservative ... for painful herniated disc revealed that while both treatments help ... pain free up to two years later. Results of the ... the annual meeting of the Radiological Society of North America ...
... CHICAGO Targeted breast ultrasound of suspicious areas of ... cost-effective alternative to invasive biopsies for women under age ... today at the annual meeting of the Radiological Society ... ultrasound, we can reduce the number of expensive and ...
... ... Ill. has become the state’s newest kidney transplant center and the first for Chicago’s ... by the Illinois Health Facilities and Services Review Board. , ... Springfield, Ill. (Vocus) -- Advocate Christ ...
Cached Medicine News:Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Personal Health Records On-Demand, In Your Pocket 2Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Long 32 mm. Overall length: 3.9 inches. Most popular size or model....
One end with needle point and other end with medium taper. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: